Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2011. The report details a specific share repurchase transaction executed on October 5, 2011, in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 129,554 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,330 pence per share; lowest price paid was 1,319.25 pence per share.
- Treasury Holdings (Settled): 505,396,816 shares (9.07% of total issued share capital).
- Treasury Holdings (Including Unsettled): 505,926,370 shares (9.99% of current total voting rights).
- Shares in Issue (Excluding Treasury): 5,064,625,635 shares.
Material Changes
The filing reports a reduction in outstanding shares due to the purchase of 129,554 shares. Consequently, the percentage of shares held in Treasury increased to 9.99% of total voting rights when including unsettled purchases. No other material changes to operations or financial position are disclosed in this document.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on future performance, or discussion of risks and contingencies. It is a routine disclosure of a share buyback transaction compliant with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total number of shares held in Treasury (505,926,370) against the company's latest capitalization table.
- Confirm the impact of the 9.99% Treasury holding on the denominator used for calculating shareholder notification thresholds under Disclosure and Transparency Rules.
- Check subsequent filings for the settlement status of the purchased shares and any further repurchase activity.